Current Issue

May 02, 2016
BioPharm International
Testing product and process intermediates alone is helpful, but does not provide a complete solution to viral safety. This article proposes integrated solutions for systemic and proactive viral risk mitigation.
May 02, 2016
BioPharm International
Cell therapy companies are attracting interest from investors, and drug companies are seeking partnerships and acquistions to accelerate development.
May 02, 2016
BioPharm International
Two main safety issues have been identified in the early-phase clinical trials conducted to date for chimeric antigen receptor (CAR)-T cell therapies.
May 02, 2016
BioPharm International
Developers of CAR-T cell therapies with products showing successful early-stage clinical results are currently seeking manufacturing capacity that will enable the production of the larger quantities of material needed for Phase III trials and eventual commercialization.
May 02, 2016
BioPharm International
Early successes drive the need to overcome safety issues, increase efficacy, and address manufacturing challenges.
May 02, 2016
BioPharm International
Policies for patient access to life-saving therapies must keep pace with biomedical innovation.
May 02, 2016
BioPharm International
Growth may be slowing, but outsourcing activity remains healthy.
May 01, 2016
BioPharm International
Siegfried Schmitt, Principal Consultant, PAREXEL International, discusses how to report quality metrics to FDA.
May 01, 2016
BioPharm International
Material compatibility, material sourcing, facility layout, and training are crucial aspects of a successful disposable fill-finish system.
May 01, 2016
BioPharm International
Data acquired from osmolality, glucose, and folic acid tests provides useful information for the specific identification of cell-culture media.
lorem ipsum